News & Updates

Women with HIV who use antiretroviral therapy (ART) combinations such as tenofovir alafenamide (TAF) with a cobicistat-boosted integrase inhibitor (INSTI) or protease inhibitor (PI) appear to frequently show somatic depressive symptoms, according to data from the Women’s Interagency HIV Study (WIHS) presented at CROI 2023.

A recent study has found a small-molecule covalently closed circular DNA (cccDNA) inhibitor that reduces levels of hepatitis B virus (HBV) cccDNA. This discovery offers a new way to cure patients with chronic HBV infection.

Combination therapy with ceftolozane and tazobactam demonstrates a favourable safety profile in children with complicated urinary tract infection (cUTI) similar to that of meropenem and to the previously reported safety profile in adults with cUTI, a study has shown.

In a systematic review and individual patient data meta-analysis, the broad-spectrum antiviral agent remdesivir reduced mortality in adult patients hospitalized for COVID-19 who did not require oxygen support or only required low-flow supplementation when the need for oxygen arose.

Arched bridge and/or vacuole signs on CT may support a diagnosis of COVID-19 pneumonia and assist in differentiation from influenza and bacterial pneumonia, a retrospective study by the Chinese University of Hong Kong has revealed. 

In the CONVIN-SING* study, there was a favourable risk-benefit ratio for COVID-19 vaccination in individuals with autoimmune inflammatory rheumatic diseases (AIIRD) who have received a COVID-19 mRNA vaccine.

In virologically suppressed adults with HIV, the cabotegravir + rilpivirine long-acting (CAB+RPV LA) regimen was on par with bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) in terms of virologic efficacy, but the former gained the upper hand over the latter in terms of patient satisfaction and preference, the SOLAR* study reports.